statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors PR Newswire SAN DIEGO, May 15...

Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors

Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights PR Newswire SAN DIEGO...

Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Avidity Biosciences to Participate in Upcoming Investor Conference Avidity Biosciences to Participate in Upcoming Investor Conference PR Newswire SAN DIEGO, May 8, 2024 SAN DIEGO, May 8, 2024...

Avidity Biosciences to Participate in Upcoming Investor Conference

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1 Avidity Biosciences Receives FDA Breakthrough...

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, April...

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Insider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Shares

This indicator may be signaling RNA's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Avidity Biosciences (RNA, $25.49) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

This is a signal that RNA's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Avidity Biosciences (RNA, $24.7) RSI Indicator left the overbought zone on March 27, 2024

This indicator may be signaling that RNA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Avidity Biosciences (RNA, $24.7) entered Downtrend as Momentum indicator drops below 0 level on Mar 27, 2024

Avidity Biosciences to Participate in Upcoming Investor Conferences Avidity Biosciences to Participate in Upcoming Investor Conferences PR Newswire SAN DIEGO, March 27, 2024 SAN DIEGO, March 27, 2024...

Avidity Biosciences to Participate in Upcoming Investor Conferences

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Watchers	1,227
52-Wk Low	$4.83
52-Wk High	$30.54

Volume	1.27M
52-Wk High	$30.54
52-Wk Low	$4.83

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.78	--	--	N/A
Q1'24	-$0.80	-$0.79	0.77%	BEAT
Q4'23	-$0.62	-$0.79	-28.41%	MISSED
Q3'23	-$0.76	-$0.71	6.17%	BEAT
Q2'23	-$0.79	-$0.66	16.78%	BEAT

RNA Avidity Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals